文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

急性肾损伤危重症患者的维生素D代谢:一项前瞻性观察性研究

Vitamin D metabolism in critically ill patients with acute kidney injury: a prospective observational study.
PubMed 文献 · Crit Care · 2024-04-02
一句话结论合并中重度AKI的危重症患者血清1,25(OH)2D显著低于无AKI者,AKI恢复后1,25(OH)2D升高,作者认为需进一步研究活性维生素D补充的获益与安全性。

这项在英国两个中心开展的前瞻性观察性研究,对合并与不合并AKI的危重症患者连续5天检测血清25(OH)D、1,25(OH)2D及血浆PTH。共分析137例患者,其中71例为AKI II/III期(23例在研究5天内肾功能恢复),66例入组时无AKI(14例新发AKI)。入组时血清25(OH)D普遍偏低(中位数18 nmol/L),有无AKI两组间无显著差异;AKI II/III期患者5天期间血清1,25(OH)2D中位数41 pmol/L(IQR 26, 58),显著低于病情相似的无AKI患者54 pmol/L(IQR 33, 69);AKI患者肾功能恢复与1,25(OH)2D浓度升高相关;血浆PTH受血清钙、镁影响,但与1,25(OH)2D水平无关。作者认为需进一步研究对中重度AKI危重症患者补充活性维生素D的健康获益与安全性。

要点

  • 中重度AKI(II/III期)危重症患者5天期间血清1,25(OH)2D中位数41 pmol/L(IQR 26, 58),显著低于病情相似的无AKI患者54 pmol/L(IQR 33, 69)。
  • 入组时全部患者血清25(OH)D普遍偏低(中位数18 nmol/L),有无AKI两组间无显著差异。
  • AKI患者肾功能恢复与血清1,25(OH)2D浓度升高相关,提示AKI状态影响活性维生素D水平。
  • 血浆PTH结果受血清钙、镁水平影响,但与1,25(OH)2D水平无关。
  • 作者认为需进一步研究对中重度AKI危重症患者补充活性维生素D的健康获益与安全性。

适用人群与场景

  • 英国两个中心收治的危重症患者,包括合并AKI与不合并AKI者。
  • AKI组为AKI II/III期患者71例,其中23例在5天研究期内肾功能恢复。
  • 非AKI组为入组时无AKI的患者66例,其中14例新发AKI。

诊断标准与关键阈值

  • AKI分期采用II/III期:71例AKI患者为AKI II/III期。

研究设计与关键结果

  • 研究类型为前瞻性观察性研究,英国两个中心,共分析137例危重症患者的连续数据。
  • 入组时患者血清25(OH)D中位数18 nmol/L,合并与不合并AKI患者之间无显著差异。
  • 5天期间血清1,25(OH)2D中位数:AKI II/III期患者41 pmol/L(IQR 26, 58) vs 病情相似的无AKI患者54 pmol/L(IQR 33, 69),AKI组显著更低。
  • AKI患者肾功能恢复与血清1,25(OH)2D浓度升高相关。
  • 血浆PTH结果受血清钙和镁水平影响,但与1,25(OH)2D水平无关。
  • AKI II/III期患者71例中23例在5天研究期内肾功能恢复;入组时无AKI的66例中14例新发AKI。

证据类型、等级与局限

  • 证据类型:前瞻性观察性研究。
  • 研究纳入两个中心,共分析137例患者,采用线性混合模型分析与敏感性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,需进一步研究对中重度AKI危重症患者补充活性维生素D的健康获益与安全性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Vitamin D deficiency in critically ill patients is associated with poor outcomes, and vitamin D supplementation is recommended for patients with chronic kidney disease. Whether acute kidney injury (AKI) is associated with altered Vitamin D metabolism is unknown. We aimed to compare the longitudinal profiles of serum 25(OH)D and 1,25(OH)2D concentrations in critically ill patients with and without moderate to severe AKI and explore the impact of renal recovery and parathyroid hormone (PTH).

METHODS: In this prospective, observational study in two centres in the UK, critically ill patients with and without AKI underwent serial measurement of serum 25(OH)D and 1,25(OH)2D and plasma PTH concentrations for 5 days. Linear mixed model analysis and sensitivity analyses were performed.

RESULTS: Serial data of 137 patients were analysed. Seventy-one patients had AKI stage II/III of whom 23 recovered kidney function during the 5-day study period; 66 patients did not have AKI at enrolment of whom 14 developed new AKI. On day of enrolment, patients' serum 25(OH)D concentrations were low (median 18 nmol/L) but there was no significant difference between patients with and without AKI. Median serum 1,25(OH)2D levels were significantly lower in patients with AKI II/III (41 pmol/L [IQR 26, 58]) compared to similarly unwell patients without AKI (54 pmol/L [IQR 33, 69]) during the 5-day period. Recovery of kidney function in patients with AKI was associated with a rise in 1,25(OH)2D concentrations. Plasma PTH results were impacted by serum calcium and magnesium levels but not associated with 1,25(OH)2D levels.

CONCLUSIONS: Critically ill patients with moderate-to-severe AKI have significantly lower serum 1,25(OH)2D concentrations than similarly sick patients without AKI but there was no difference in serum 25(OH)D concentrations. Recovery of AKI was associated with a rise in serum 1,25(OH)2D concentrations. More research is needed to investigate the health benefits and safety of supplementation with active vitamin D in critically ill patients with moderate-to-severe AKI. Trial registration Clinicaltrials.gov (NCT02869919), registered on 16 May 2016.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Cameron LK, Ledwaba-Chapman L, Voong K, et al. Vitamin D metabolism in critically ill patients with acute kidney injury: a prospective observational study. Crit Care. 2024. PMID: 38566240. doi:10.1186/s13054-024-04869-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。